Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
By Elana Gotkine HealthDay Reporter
.jpg?width=1200)
THURSDAY, Oct. 31, 2024 -- For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo, according to a study published in the Oct. 31 issue of the New England Journal of Medicine.
Henning Bliddal, M.D., from the Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, and colleagues conducted a 68-week trial at 61 sites in 11 countries. Four hundred seven participants with obesity and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned to receive once-weekly subcutaneous semaglutide or placebo in a 2:1 ratio in addition to counseling on physical activity and a reduced-calorie diet.
The researchers found that from baseline to week 68, the mean change in body weight was −13.7 and −3.2 percent with semaglutide and placebo, respectively. At week 68, the mean change in the Western Ontario and McMaster Universities Osteoarthritis Index pain score was −41.7 and −27.5 points with semaglutide and placebo, respectively. Greater improvement in the 36-Item Short Form Health Survey physical-function score was seen for participants in the semaglutide group versus placebo group (mean change, 12.0 versus 6.5 points). The two groups had a similar incidence of serious adverse events.
"The findings support the use of once-weekly subcutaneous semaglutide at a dose of 2.4 mg for weight management and treatment of pain in persons with obesity and moderate-to-severe pain due to knee osteoarthritis," the authors write.
The study was funded by Novo Nordisk, the manufacturer of semaglutide.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Prevalence of Extremely Severe Obesity Increasing in Children
TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...
Long-Term Obesity Linked to Expression of Aging Biomarkers
THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.